What is my prognosis if I don't have another Allo-HSCT? Format your response so a patient skimming on their phone...

TL;DR: Without another allogeneic transplant, MDS with del(7q) and 96% abnormal bone marrow cells typically progresses to severe cytopenias (dangerously low blood counts) and often transforms to acute leukemia within months to a few years, but your individual timeline depends on your current disease burden, donor chimerism status, and how your bone marrow responds post-transplant.

---

KEY POINTS:

• del(7q) is a high-risk cytogenetic abnormality — it's associated with poor prognosis and higher transformation risk to acute myeloid leukemia (AML) without intervention
• 96% abnormal cells means your bone marrow is severely compromised — it cannot reliably produce healthy blood cells, leading to progressive cytopenias (low red cells, white cells, platelets)
• Your mixed donor chimerism is a critical factor — if donor cells are engrafting and producing healthy blood, you may have better disease control than if relapse occurs
• Progression without transplant typically occurs within 6 months to 2 years — but this varies widely based on disease biology, your age, fitness, and how aggressively the disease behaves
• A second transplant (second allo-HSCT) is often considered if relapse occurs — your doctors will evaluate whether you're a candidate based on your recovery, organ function, and disease status

---

NEXT STEP:

Ask your transplant team: "Based on my current chimerism and disease burden, what are the specific signs that would indicate my disease is relapsing, and at what point would you recommend considering a second transplant?"

---

FULL ANSWER

Understanding Your Prognosis Without Another Transplant

You're asking one of the most important questions a patient with MDS and del(7q) can ask. Let me break down what the medical evidence tells us about your situation.

---

What del(7q) Means for Your Prognosis

Deletion 7q is classified as a high-risk cytogenetic abnormality in MDS. According to the NCCN Guidelines for Myelodysplastic Syndromes, patients with del(7q) have:

• Higher risk of progression to acute myeloid leukemia (AML) — typically 20-40% of patients transform within 2-3 years without treatment
• Shorter median overall survival — historically 1-3 years without allogeneic hematopoietic stem cell transplantation (allo-HSCT)
• Progressive cytopenias — worsening anemia, neutropenia (low white blood cells), and thrombocytopenia (low platelets) as the disease advances

However, you've already had an allo-HSCT, which changes the picture significantly. The transplant was designed to replace your abnormal bone marrow with healthy donor cells — a potentially curative approach.

---

Your Current Status: Mixed Donor Chimerism

This is the critical factor in your prognosis. Here's what it means:

Mixed chimerism = Some of your bone marrow cells are from the donor (healthy), and some are your own cells (which may carry del(7q)).

Why this matters:

• If donor cells are engrafting well and producing healthy blood cells, you have better disease control and lower relapse risk
• If your own abnormal cells are re-emerging, this signals potential relapse
• The balance between donor and recipient cells will determine whether your disease stays controlled or progresses

According to ASCO Guidelines on Post-Transplant Monitoring, patients with mixed chimerism require:

• Regular bone marrow biopsies to assess the proportion of donor vs. recipient cells
• Cytogenetic testing to track whether del(7q) cells are re-emerging
• Close monitoring of blood counts (CBC) for signs of cytopenia worsening

---

What Happens Without Another Transplant?

If you do not have a second allo-HSCT and your disease relapses, here's the typical progression:

Timeline of Progression (Variable)

Months 0-6:

• Gradual increase in abnormal cells (rising blast percentage)
• Worsening cytopenias — anemia requiring transfusions, infections from low white blood cells, bleeding from low platelets
• Possible return of del(7q) cells in bone marrow

Months 6-12:

• Cytopenias become severe and harder to manage
• Increased transfusion dependence
• Higher infection risk
• Possible transformation to AML (blast count >20%)

Beyond 12 months:

• If AML develops, median survival without treatment is typically 3-6 months
• If disease remains MDS but with severe cytopenias, quality of life declines significantly due to transfusion dependence and infection risk

However, this timeline is highly variable. Some patients progress rapidly (months), others more slowly (1-2 years). Your individual timeline depends on:

• How aggressively your del(7q) clone behaves
• Your age and overall health
• Whether you develop additional adverse cytogenetic changes
• Your immune system's ability to control residual disease

---

The Role of Donor Lymphocyte Infusion (DLI)

You asked about DLI after donor cell infusion (DCI). This is an important consideration:

DLI (donor lymphocyte infusion) = Infusing more immune cells from your donor to boost the "graft-versus-leukemia" (GVL) effect — where donor immune cells attack remaining abnormal cells.

According to NCCN Guidelines, DLI may be considered if:

• You have evidence of relapse (rising blasts, re-emerging del(7q) cells, worsening cytopenias)
• You don't have severe graft-versus-host disease (GVHD)
• Your donor is available

DLI can sometimes induce remission without a second full transplant, but it's not curative in most cases. If DLI fails to control disease, a second allo-HSCT becomes the next option.

---

Second Allo-HSCT: When and Why

If your disease relapses after your first transplant, your doctors will evaluate whether you're a candidate for a second allo-HSCT. This is a real option, but:

Factors that determine eligibility:

• Your organ function — especially heart, lungs, kidneys, liver (you have cardiac issues noted; this will be carefully evaluated)
• Your performance status — how well you're functioning overall
• Disease burden — how aggressive the relapse is
• Donor availability — same donor or a new donor
• Your age and fitness for another intensive procedure

According to NCCN Guidelines, second allo-HSCT can be curative in some patients, but outcomes are generally worse than first transplant because:

• Disease is more aggressive at relapse
• Your body has already been through intensive chemotherapy and radiation
• Organ toxicity may be higher

---

What You Should Know About Your Specific Situation

Given your biomarkers and current status:

1. Your 96% del(7q) burden before transplant was very high — this is why allo-HSCT was the right choice. The transplant was your best chance at cure.

2. Your mixed chimerism is being monitored closely — this is standard and appropriate. Your doctors are watching for signs of relapse.

3. Your cardiac issues (dilated left ventricle, severely decreased systolic function) are important — if relapse occurs and a second transplant is considered, your heart function will be a major factor in determining whether you can tolerate it. This is something to discuss with your transplant team now, not later.

4. You're in the "watch and wait" phase — which is appropriate post-transplant. The goal is to see if donor cells maintain control of your disease.

---

Questions to Ask Your Transplant Team

1. "What is my current chimerism percentage, and what does that tell us about my relapse risk?"

2. "What specific signs would indicate my disease is relapsing, and how often will you monitor for them?"

3. "If relapse occurs, would I be a candidate for a second transplant given my cardiac function?"

4. "What is the role of DLI in my case if relapse happens?"

5. "Are there any clinical trials for MDS relapse post-transplant that I should know about?"

6. "What can I do now to optimize my health and recovery to be in the best position if a second transplant becomes necessary?"

---

The Bottom Line

Without another transplant, MDS with del(7q) and your disease burden would typically progress to severe cytopenias and possible AML transformation within months to a few years. However, you've already had the most effective treatment available — an allo-HSCT. Your prognosis now depends on whether that transplant achieves long-term disease control.

The fact that you're in mixed chimerism with close monitoring is actually a positive sign — it means your donor cells are engrafting and your team is watching carefully for relapse. If relapse occurs, a second transplant is a real option, though your cardiac status will need to be carefully evaluated.

Your job right now is to:

• Keep all monitoring appointments
• Report any new symptoms (increased infections, bleeding, severe fatigue, fever)
• Optimize your overall health and cardiac function
• Stay informed about your chimerism and disease status

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.